We next determined in vitro synergistic activity of co-treatment with SNDX-50469 and the pan-BET protein inhibitor OTX015 against AML cell lines and PD AML cells expressing MLL-FP or NPM1c. This evidence concerns the gene KMT2A and acute myeloid leukemia.